[go: up one dir, main page]

WO2009138198A2 - Compositions comprenant de l'hydroxytyrosol pour le traitement préventif et curatif de troubles du tractus intestinal - Google Patents

Compositions comprenant de l'hydroxytyrosol pour le traitement préventif et curatif de troubles du tractus intestinal Download PDF

Info

Publication number
WO2009138198A2
WO2009138198A2 PCT/EP2009/003317 EP2009003317W WO2009138198A2 WO 2009138198 A2 WO2009138198 A2 WO 2009138198A2 EP 2009003317 W EP2009003317 W EP 2009003317W WO 2009138198 A2 WO2009138198 A2 WO 2009138198A2
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
intestinal tract
hydroxytyrosol
preventive
soluble dietary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/003317
Other languages
English (en)
Other versions
WO2009138198A3 (fr
Inventor
Felicia Cisale
Luciano Villanova
Azzurra Villanova
Alessandro Merendino
Gianluca Fasiello
Luigi Villanova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lachifarma Srl Laboratorio Chimico Farmaceutico Salentino
Original Assignee
Lachifarma Srl Laboratorio Chimico Farmaceutico Salentino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lachifarma Srl Laboratorio Chimico Farmaceutico Salentino filed Critical Lachifarma Srl Laboratorio Chimico Farmaceutico Salentino
Publication of WO2009138198A2 publication Critical patent/WO2009138198A2/fr
Publication of WO2009138198A3 publication Critical patent/WO2009138198A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • the present invention relates to oral compositions with enhanced release in the intestinal tract which contain hydroxytyrosol as the active ingredient, and possibly a soluble dietary fibre.
  • Prior art Hydroxytyrosol (or 3,4-dihydroxyphenylethanol) is a known antioxidant agent present in olive oil.
  • HT hydroxytyrosol
  • EP 1623960 A process intended to prepare high-purity hydroxytyrosol suitable as an ingredient for use in the pharmaceutical, dietary and cosmetic fields is disclosed in EP 1623960, filed by the Applicant.
  • EP 1623960 also discloses formulations containing HT for applications in the pharmaceutical, dietary and cosmetic fields.
  • the present invention therefore relates to oral compositions with enhanced release in the intestinal tract which contain hydroxytyrosol as active ingredient, and possibly a soluble dietary fibre.
  • the compositions according to the invention may include a soluble dietary fibre, such as guar gum, glucomannan or chicory extract. Said fibres act as carriers of HT to the intestinal tract, and also perform a useful probiotic and intestine-regulating function.
  • the soluble fibres gel in the intestinal tract where they are not digested, thus giving the formulations pseudoplastic characteristics which allow the release of HT in the target areas.
  • compositions of HT and fibres may be in liquid or granulate form.
  • the formulations may take the form of gastroresistant tablets prepared with conventional polymer coatings, for example using a film-forming solution of hydroxypropyl methylcellulose phthalate in ethanol.
  • compositions according to the invention may contain 0.1 to 10% of HT formulation per unit dose, and 0.1 to 1500 mg of soluble dietary fibres.
  • compositions according to the invention can be formulated suitably for oral administration, and prepared according to conventional methods well known in pharmaceutical technology, such as those described in Remington's
  • Example 1 Liquid preparation of HT + dietary fibre as carrier
  • Example 2 Granular preparation of HT + dietary fibre as carrier
  • Example 3 Gastroresistant tablet containing HT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des compositions orales présentant une libération améliorée dans le tractus intestinal, lesquelles contiennent de l'hydroxytyrosol comme principe actif, et, le cas échéant, des fibres alimentaires solubles.
PCT/EP2009/003317 2008-05-14 2009-05-11 Compositions comprenant de l'hydroxytyrosol pour le traitement préventif et curatif de troubles du tractus intestinal Ceased WO2009138198A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2008A000869 2008-05-14
IT000869A ITMI20080869A1 (it) 2008-05-14 2008-05-14 Composizioni a base di idrossitirosolo per il trattamento preventivo e curativo di patologie del tratto intestinale

Publications (2)

Publication Number Publication Date
WO2009138198A2 true WO2009138198A2 (fr) 2009-11-19
WO2009138198A3 WO2009138198A3 (fr) 2010-03-04

Family

ID=40302738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/003317 Ceased WO2009138198A2 (fr) 2008-05-14 2009-05-11 Compositions comprenant de l'hydroxytyrosol pour le traitement préventif et curatif de troubles du tractus intestinal

Country Status (2)

Country Link
IT (1) ITMI20080869A1 (fr)
WO (1) WO2009138198A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4587200B2 (ja) * 2001-10-09 2010-11-24 株式会社ファンケル グルタチオン増強用組成物
ITMI20041627A1 (it) * 2004-08-06 2004-11-06 Lachifarma S R L Lab Chimi Co Processo per il recupero di tirosolo idrossitirosolo e altri componenti fenolici da acque di vegetazione e metodo di ossidazione catalitica di tirosolo a idrossitirosolo
WO2008006581A2 (fr) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Nouvelles compositions
EP2027781A1 (fr) * 2007-08-21 2009-02-25 DSMIP Assets B.V. Procédé pour éliminer le goût amer de l'extrait de jus d'olive

Also Published As

Publication number Publication date
WO2009138198A3 (fr) 2010-03-04
ITMI20080869A1 (it) 2009-11-15

Similar Documents

Publication Publication Date Title
Kamal et al. Chemotherapeutic and chemopreventive potentials of ρ-coumaric acid–Squid chitosan nanogel loaded with Syzygium aromaticum essential oil
CN104379175B (zh) 高度支化的α-D-葡聚糖
US9486434B2 (en) Method for delivery and use of isothiocyanates for prophylaxis and/or therapy of bladder cancer
Nanavati Phytosome: a novel approach to enhance the bioavailability of phytoconstituent
KR20200095476A (ko) 식물계 지방산 공급원을 포함하는 식이 조성물
JP2017506241A (ja) ウコンならびにホソババレンギクの抽出物を含有する、末梢性炎症ならびに疼痛の軽減に有用な組成物
WO2009062662A1 (fr) Compositions pharmaceutiques et nutraceutiques à base de ménaquinols
WO2009138198A2 (fr) Compositions comprenant de l'hydroxytyrosol pour le traitement préventif et curatif de troubles du tractus intestinal
Harney Resveratrol and Curcumin: Extending the Frontier of Phytomedicine
Kemkar et al. 6-Shogaol rich ginger oleoresin loaded mixed micelles enhances in vitro cytotoxicity on mcf-7 cells and in vivo anticancer activity against dal cells
JP6641626B2 (ja) 制酸用医薬組成物
Kuchekar et al. Formulation and evaluation of Norfloxacin Dispersible tablets using Natural substances as Disintegrants
ES2905407T3 (es) Composiciones que contienen curcumina con biodisponibilidad mejorada
KR20140094775A (ko) 수용성 키토산을 유효성분으로 함유하는 항암 또는 항염 활성을 갖는 약학적 조성물
Roy et al. Phytoconstituent based mucoadhesive antifungal vaginal formulation: An effective and innovative approach
AU2017239585B2 (en) Curcuminoid compositions and preparation methods
US20190192588A1 (en) Synergistic curcuminoids and probiotic compositions
WO2021049768A1 (fr) Nanocapsule revêtue de chitosane contenant du rétinol ou un dérivé de rétinol, et son utilisation
JP7475824B2 (ja) 組成物
Bamigbade et al. Selenium nanoparticles stabilized by date pulp polysaccharides: Bioactivities, gut microbiota modulation and short chain fatty acids production
RU2681649C1 (ru) Композиция на основе празиквантеля для лечения описторхоза
EP3678498A1 (fr) Composition pour supplémentation de calcium
Zayed et al. Comparative study of the cytoto xicity and apoptotic effect of beet root, and silica-beet nanopartic les with 5-FU nanopartic les against Scc-090 cell line
Zayed et al. Comparative study of the cytotoxicity and apoptotic effect of beet root, and silica-beet nanoparticles with 5-FU nanoparticles against Scc-090 cell line
Ordu et al. Evaluation of Cochorus Olitorious Derived Polymer as an Excipient in Micro/Nano Suspension Formulation of Metronidazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09745532

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09745532

Country of ref document: EP

Kind code of ref document: A2